@article{96a1cbcc64974d2fba03ed047f279c53,
title = "Generalised Anxiety Disorder and Depression: Contemporary Treatment Approaches",
keywords = "Generalised anxiety disorder, Major depressive disorder, Pharmacotherapy",
author = "Goodwin, \{Guy M.\} and Stein, \{Dan J.\}",
note = "Funding Information: This supplement has been sponsored by Servier, France. This funding includes payment of the journal{\textquoteright}s Rapid Service Fee and Open Access Fee. We would like to thank Richard Crampton of Springer Healthcare Communications, who wrote the first draft of this article. Funding for this medical writing assistance was provided by Servier. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Prof Goodwin and Dr Stein each prepared one of the lectures on which this editorial is based, and both authors read and revised all drafts of this editorial and approved the final draft for submission. This editorial and the accompanying articles in this supplement are based on presentations made by the authors at a Servier-funded virtual symposium titled {\textquotedblleft}GAD and Depression: Contemporary Treatment Approaches{\textquotedblright} as part of the Industry Science Exchange sessions that took place at the European College of Neuropsycopharmacology 33rd Congress in September 2020. Guy M. Goodwin is a NIHR Emeritus Senior Investigator and Medical Director at P1vital products, holds shares in P1vital and P1vital products, has served as consultant, advisor or CME speaker in the last 3 years for Beckley Psytech, Clerkenwell Health, Compass pathways, Evapharma, Janssen, Lundbeck, Medscape, Novartis, Ocean Neuroscience, P1Vital, Sage, and Servier, and has received an honorarium from Servier for the presentation on which this publication is based. Dan J. Stein has received research grants and/or consultancy honoraria from Abbott, ABMRF/The Foundation for Alcohol Research, AstraZeneca, Biocodex, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson \& Johnson, Lundbeck, National Responsible Gambling Foundation, Novartis, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Sun, Takeda, Tikvah and Wyeth, and has received research grants and/or consultancy honoraria in the last 3 years from Johnson \& Johnson, Lundbeck, Servier and Takeda. This includes an honorarium from Servier for the presentation on which this publication is based. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. This editorial is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.",
year = "2021",
month = sep,
doi = "10.1007/s12325-021-01859-8",
language = "English",
volume = "38",
pages = "45--51",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Adis",
}